Myambutol

(Ethambutol)

ApprovedSmall molecule

VVA Greater Los Angeles Healthcare System

Ethambutol is used to treat tuberculosis (TB) infection, usually in combination with other antibiotics. It helps stop the growth of the bacteria that causes TB.[2] Myambutol is currently approved and in use across 13 indications[4].[1]

Myambutol is one of 303 small molecule programs targeting Abscess. It is currently in Approved.

Indications

Total Trials

Active Trials

302

Competitors

FDA Application

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[4][1]

Indication

AbscessActive, not recruiting

Anterior UveitisActive, not recruiting

Mycobacterium Avium Complex DiseaseActive, not recruiting

Mycobacterium InfectionApproved

Lung DiseaseActive, not recruiting

Pulmonary SarcoidosisActive, not recruiting

Pulmonary TuberculosisActive, not recruiting

ImmunodeficiencyActive, not recruiting

Cystic FibrosisActive, not recruiting

HIVTerminated

AbscessPhase 2/Phase 3

Active, not recruiting

Anterior UveitisPhase 3

Active, not recruiting

Mycobacterium Avium Complex DiseasePhase 2/Phase 3

Active, not recruiting

Mycobacterium InfectionApproved

Approved

Lung DiseasePhase 2/Phase 3

Active, not recruiting

Pulmonary SarcoidosisPhase 2

Active, not recruiting

Pulmonary TuberculosisApproved

Active, not recruiting

ImmunodeficiencyPhase 2

Active, not recruiting

Cystic FibrosisPhase 2

Active, not recruiting

HIVPhase 2

Terminated

Showing 10 of 13 indications

Competition

Competitive Landscape

392 competitors in Obesity

#DrugCompanyPhaseTrials

Myambutol

VVA Greater Los Angeles Healthcare System

Approved

1 2

Actemra

Roche

Preclinical

2 3

Avapro

Sanofi

Preclinical

1 4

Activella

Eli Lilly

Preclinical

—5

Colcrys

Alnylam Pharmaceuticals

Cetrotide

2 7

Advil

KKenvue Brands

Preclinical

1 8

Prometrium

Ferring

Preclinical

1 9

Spravato

WWim Janssens

Preclinical

1 10

Firmagon

Ferring

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 3Not yet recruiting

Pulmonary Tuberculosis

NCT04485156

Phase 3Active, not recruiting

Tuberculosis

NCT06081361

Q1 2027

Phase 2Active, not recruiting

Drug

NCT05556746

Q3 2027

Phase 3Recruiting

Children

NCT06253715

Phase 2Recruiting

ESS

NCT06114628

Phase 2Recruiting

Pulmonary Tuberculosis

NCT06192160

Clinical

Trials by Indication[1]

Tuberculosis15 trials

Rosuvastatin Evaluation as a Tuberculosis Treatment Adjunct

Unknown status·NNational University Hospital, Singapore·Phase 2·NCT04504851·154 enrolled

Two-month Regimens Using Novel Combinations to Augment Treatment Effectiveness for Drug-sensitive Tuberculosis

Completed·UUniversity College, London·Phase 2/3·NCT03474198·675 enrolled

The Optimal Duration of Preoperative Anti-tuberculosis Treatment of Spinal Tuberculosis

Unknown status·—·Phase 4·NCT02477852·400 enrolled

Show 12 more trials

Efficacy and Safety of Intravenous Treatment of Tuberculosis

Terminated·YYuria-Pharm··NCT04150367·166 enrolled

Short-Course Anti-tuberculosis Regimens for Mild Spinal Tuberculosis

Not yet recruiting·SShandong University·Phase 2·NCT06917495·300 enrolled

Linezolid Instead of Ethambutol in Treatment of Drug-susceptible Tuberculosis

Unknown status·SSeoul National University Hospital·Phase 2·NCT01994460·429 enrolled

Pharmacokinetic and Pharmacodynamic Study of High-Dose Rifapentine and Moxifloxacin for Treatment of Tuberculosis

Completed·CCenters for Disease Control and Prevention·Phase 3·NCT02563327·53 enrolled

Innovating Shorter, All- Oral, Precised, Individualized Treatment Regimen for Rifampicin Resistant Tuberculosis：Contezolid, Delamanid and Bedaquiline Cohort

Active, not recruiting·—·Phase 3·NCT06081361·186 enrolled

Sitafloxacin-containing Regimens for Shortening Tuberculosis Treatment

Not yet recruiting·FFirst Affiliated Hospital of Zhejiang University·Phase 3·NCT05454345·620 enrolled

Rifampin-Based Tuberculosis Treatment Versus Rifabutin-Based Tuberculosis Treatment in Persons With HIV

Terminated·AAdvancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections·Phase 2·NCT01601626·71 enrolled

Short-Course Regimen With Bedaquiline, Moxifloxacin and Pyrazinamide for Early Bactericidal Activity in Drug-Susceptible Tuberculosis

Not yet recruiting·SShanghai Pulmonary Hospital, Shanghai, China·Phase 2·NCT07129629·45 enrolled

Building Evidence for Advancing New Treatment for Rifampicin Resistant Tuberculosis (RR-TB) Comparing a Short Course of Treatment (Containing Bedaquiline, Delamanid and Linezolid) With the Current South African Standard of Care

Completed·WWits Health Consortium (Pty) Ltd·Phase 3·NCT04062201·402 enrolled

The Evaluation of a Standard Treatment Regimen of Anti-tuberculosis Drugs for Patients With MDR-TB

Completed·IIUATLD, Inc·Phase 3·NCT02409290·588 enrolled

Tuberculosis Treatment Shortening Trial

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 3·NCT00130247·394 enrolled

Assessing PA-824 for Tuberculosis (the APT Trial)

Completed·JJohns Hopkins University·Phase 2·NCT02256696·157 enrolled

Pulmonary Tuberculosis7 trials

Short-course Regimens for the Treatment of Pulmonary Tuberculosis

Active, not recruiting·CCenters for Disease Control and Prevention·Phase 2/3·NCT05766267·288 enrolled

Shortened Regimens for Drug-susceptible Pulmonary Tuberculosis

Unknown status·—·Phase 4·NCT02901288·3,900 enrolled

Treatment Shortening of Drug-Sensitive Pulmonary Tuberculosis Using High Dose Rifampicin (Hi-DoRi-3)

Not yet recruiting·SSeoul National University Hospital·Phase 3·NCT04485156·926 enrolled

Show 4 more trials

Fermented Soybean Supplementation Among Active Pulmonary Tuberculosis Patients With Standard Therapy in Indonesia

Completed·UUniversity of Giessen·N/A·NCT02554318·147 enrolled

A Randomised Trial to Evaluate Toxicity and Efficacy of 1200mg and 1800mg Rifampicin for Pulmonary Tuberculosis

Completed·SSt George's, University of London·Phase 3·NCT02581527·672 enrolled

Four Months Moxifloxacin Containing Daily Regimen Study Among New Pulmonary Tuberculosis Patients

Unknown status·TTuberculosis Research Centre, India··NCT05047055·550 enrolled

A Phase 2 Randomized, Adaptive, Dose-Ranging, Open-Label Trial of Novel Regimens for the Treatment of Pulmonary Tuberculosis

Recruiting·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT06192160·315 enrolled

Mycobacterium Avium Complex3 trials

CLArithromycin Versus AZIthromycin in the Treatment of Mycobacterium Avium Complex (MAC) Lung Infections

Recruiting·—·Phase 3·NCT03236987·424 enrolled

Study to Evaluate ALIS (Amikacin Liposome Inhalation Suspension) in Participants With Nontuberculous Mycobacterial Lung Infection Caused by Mycobacterium Avium Complex

Completed·IInsmed Incorporated·Phase 3·NCT04677569·425 enrolled

Validation of Patient Reported Outcome Measures in Participants With Nontuberculous Mycobacterial Lung Infection Caused by Mycobacterium Avium Complex

Completed·IInsmed Incorporated·Phase 3·NCT04677543·99 enrolled

Mycobacterium Avium Complex Pulmonary Disease2 trials

Phase II Study of Amithiozone (Thiacetazone) for Patients With Mycobacterium Avium Complex Pulmonary Disease

Completed·NNational Jewish Health·Phase 2·NCT00004689·50 enrolled

Short-term Antibiotic Therapy in Mycobacterium Avium Complex Pulmonary Disease

Recruiting·BBin Cao·Phase 4·NCT07213765·188 enrolled

Drug2 trials

Ultra-Short Course Bedaquiline, Clofazimine, Pyrazinamide and Delamanid Versus Standard Therapy for Drug-Susceptible TB

Active, not recruiting·—·Phase 2·NCT05556746·94 enrolled

PK Study of Anti-TB Drugs

Completed·UUniversity of Oxford·Phase 1·NCT02457208·61 enrolled

22 more indications

Cystic Fibrosis2 trials

Testing a Novel Combination Treatment (Arm D) Versus Standard of Care for Intensive Phase Treatment for Mycobacterium Abscessus Pulmonary Disease in People With or Without Cystic Fibrosis in the Finding the Optimal Regimen for Mycobacterium Abscessus Treatment (FORMaT) Adaptive Platform Trial

Not yet recruiting·TThe University of Queensland·Phase 2·NCT07485010·300 enrolled

Improving Treatment of Nontuberculous Mycobacterial Infection in Cystic Fibrosis

Completed·UUniversity of Colorado, Denver·N/A·NCT02372383·31 enrolled

Obesity1 trial

Effect of Weight and/or Obesity on Ethambutol Drug Concentrations

Completed·TTexas Tech University Health Sciences Center·Phase 4·NCT01048697·18 enrolled

Anterior Uveitis1 trial

Multicenter, Randomized Study Evaluating the Value of Antitubercular Treatment During Recurent Anterior Uveitis (URBA)

Unknown status·AAssistance Publique - Hôpitaux de Paris·Phase 3·NCT04117698·116 enrolled

Resistance1 trial

TBTC Study 24: Intermittent Treatment of TB With Isoniazid Resistance or Intolerance

Completed·CCenters for Disease Control and Prevention·N/A·NCT00023374·98 enrolled

Children1 trial

Shortened Regimen for Drug-susceptible TB in Children

Recruiting·JJohns Hopkins University·Phase 3·NCT06253715·860 enrolled

Mycobacterium avium complex disease1 trial

Comparison of Two- Versus Three-antibiotic Therapy for Pulmonary Mycobacterium Avium Complex Disease

Completed·KKevin Winthrop·Phase 2/3·NCT03672630·474 enrolled

Immunodeficiency1 trial

Safety and Tolerability of Metformin in People With Tuberculosis (TB) and Human Immunodeficiency Virus (HIV)

Completed·UUniversity of Massachusetts, Worcester·Phase 2·NCT04930744·112 enrolled

Lung Disease1 trial

A Study of Bedaquiline Administered as Part of a Treatment Regimen With Clarithromycin and Ethambutol in Adult Patients With Treatment-refractory Mycobacterium Avium Complex-lung Disease (MAC-LD)

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 2/3·NCT04630145·129 enrolled

Pulmonary Sarcoidosis1 trial

Phase II Investigation of Antimycobacterial Therapy on Progressive, Pulmonary Sarcoidosis

Completed·VVanderbilt University·Phase 2·NCT02024555·97 enrolled

Pregnancy1 trial

Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)··NCT00042289·1,578 enrolled

Azithromycin1 trial

A Study to Evaluate the Effect of Co-administration on the Pharmacokinetics of SPR720, Azithromycin, and Ethambutol in Healthy Participants

Completed·SSpero Therapeutics·Phase 1·NCT05966688·39 enrolled

Meningitis1 trial

Trial of a Six-Month Regimen of High-Dose Rifampicin, High-Dose Isoniazid, Linezolid, and Pyrazinamide Versus a Standard Nine-Month Regimen for the Treatment of Adults and Adolescents With Tuberculous Meningitis

Recruiting·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT05383742·330 enrolled

ESS1 trial

Platform Assessing Regimens and Durations In a Global Multisite Consortium for TB

Recruiting·UUniversity College, London·Phase 2·NCT06114628·2,500 enrolled

Elderly1 trial

Ultra-Short Regimen for Elderly DS-TB

Not yet recruiting·SShenzhen Third People's Hospital·Phase 3·NCT07076225·300 enrolled

Treatment Duration1 trial

Optimal Treatment Duration for Radiographically Apparent, Bacteriologically Unconfirmed TB, Identified Through Active Case Finding (RADIO-TB Trial)

Not yet recruiting·UUniversity College, London·Phase 3·NCT07163143·784 enrolled

Trial1 trial

A PAN-USR TB Multi-Center Trial

Recruiting·SShenzhen Third People's Hospital·Phase 3·NCT06905522·610 enrolled

NAC1 trial

PanACEA - STEP2C -01

Recruiting·MMichael Hoelscher·Phase 2·NCT05807399·390 enrolled

Abscess1 trial

Finding the Optimal Regimen for Mycobacterium Abscessus Treatment

Recruiting·TThe University of Queensland·Phase 2/3·NCT04310930·300 enrolled

TIA1 trial

Essentiality of INH in TB Therapy

Completed·AAdvancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections·Phase 2·NCT01589497·69 enrolled

Pulmonary TB1 trial

Evaluation of SQ109, High-dose Rifampicin, and Moxifloxacin in Adults With Smear-positive Pulmonary TB in a MAMS Design

Completed·MMichael Hoelscher·Phase 2·NCT01785186·365 enrolled

HIV1 trial

A Phase IIc Trial of Clofazimine- and Rifapentine-Containing Treatment Shortening Regimens in Drug-Susceptible Tuberculosis: The CLO-FAST Study

Terminated·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT04311502·104 enrolled

Unspecified2 trials

Short-term Bactericidal Effect of Contezolid in MAC-PD

Recruiting·BBin Cao·Phase 4·NCT07084402·188 enrolled

Hypertonic Saline for MAC

Recruiting·OOregon Health and Science University·Phase 4·NCT04921943·50 enrolled

Regulatory

FDA Approval Timeline[5]

Jan 1, 1982

MYAMBUTOL

NDA NDA016320

Sources

References

[1]
ClinicalTrials.gov — 53 trial records for Ethambutol. U.S. National Library of Medicine, National Institutes of Health.
[2]
MedlinePlus Drug Information — Myambutol drug information. U.S. National Library of Medicine, National Institutes of Health.
[3]
ChEMBL — Ethambutol compound record. European Bioinformatics Institute (EMBL-EBI).
[4]
Open Targets Platform — Drug–disease associations for Ethambutol. EMBL-EBI & Wellcome Sanger Institute.
[5]
OpenFDA — FDA approval records (NDA NDA016320). U.S. Food & Drug Administration.
[6]
SEC EDGAR — VA Greater Los Angeles Healthcare System company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Mechanism of Action: Arabinosyltransferase a Inhibitor[3]
Modality: Small molecule[3]
Highest Phase: Approved[1]
Company: VVA Greater Los Angeles Healthcare System

Myambutol

Status by Indication[4][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q1 2027

Q3 2027

Trials by Indication[1]

Tuberculosis15 trials

Pulmonary Tuberculosis7 trials

Mycobacterium Avium Complex3 trials

Mycobacterium Avium Complex Pulmonary Disease2 trials

Drug2 trials

Cystic Fibrosis2 trials

Obesity1 trial

Anterior Uveitis1 trial

Resistance1 trial

Children1 trial

Mycobacterium avium complex disease1 trial

Immunodeficiency1 trial

Lung Disease1 trial

Pulmonary Sarcoidosis1 trial

Pregnancy1 trial

Azithromycin1 trial

Meningitis1 trial

ESS1 trial

Elderly1 trial

Treatment Duration1 trial

Trial1 trial

NAC1 trial

Abscess1 trial

TIA1 trial

Pulmonary TB1 trial

HIV1 trial

Unspecified2 trials

FDA Approval Timeline[5]

References

Drug Info

Quick Facts

Related News